RPL17 and melanoma: CPI therapy targeting CTLA-4 and PD-1 has improved clinical outcomes in patients with BM [1], including objective responses in patients (pts) with active, untreated melanoma or non-small cell lung cancer (NSCLC) BM [2-4].